The Influence of Bosentan on MicroRNA-27a/PPARγ/ET-1 Signaling Pathway in Pulmonary Artery Hypertension
Authors:
- 15 April 2021
- journal article
- research article
- Published by Springer Nature in Pediatric Cardiology
- Vol. 42 (5) , 1141-1148
Abstract
Pulmonary artery hypertension (PAH) is a common and serious disease which is characterized by pulmonary vascular remodeling. Bosentan (BST) is the first approved oral targeted drug of endothelin-1 (ET-1) receptor antagonists for the treatment of PAH. MicroRNA-27a (miR-27a) and peroxisome proliferator-activated receptor γ (PPARγ) were found to be related to the pathogenesis of PAH. To further explore the signal transduction mechanism of BST in the treatment of PAH, we examined the effects of BST on endothelin receptors, miR-27a, and PPARγ. Meanwhile, the influence of miR-27a in the formation and development of PAH was discussed. Our results demonstrated that during the pathophysiology of PAH, miR-27a, PPARγ, and ET-1 were cross-inhibited, which indicated that the miR-27a/PPARγ/ET-1 signaling pathway was dysregulated; in addition, BST could competitively bind to ET-1 receptors and inhibit the miR-27a/PPARγ/ET-1 signaling pathway, thereby delaying the proliferation of PASMCs and affecting the development of PAH. Our results give a new understanding of the pathogenesis and treatment of PAH and provide more reliable evidence for the application of BST in the treatment of PAH in the clinic.Keywords
Funding Information
- Shandong Key Research and Development Plan (2019GSF108186 2014GSF118066)
- Science Foundation of Qilu Hospital of Shandong University (2017QLQN33)
This publication has 29 references indexed in Scilit:
- Hypoxia Mediates Mutual Repression between microRNA-27a and PPARγ in the Pulmonary VasculaturePLOS ONE, 2013
- Circulating miRNAs as Potential Marker for Pulmonary HypertensionPLOS ONE, 2013
- Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in miceCell Research, 2011
- Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseasesMolecular Cancer, 2010
- Rosiglitazone attenuates hypoxia‐induced pulmonary arterial hypertension in ratsRespirology, 2010
- Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and MonocrotalineArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- MicroRNA Regulation of Cardiovascular DevelopmentCirculation Research, 2009
- An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertensionJournal of Clinical Investigation, 2008
- Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodelingAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activationBritish Journal of Pharmacology, 2004